ST 045849

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 471036

CAS#: 442665-87-4

Description: ST 045849 is an O-GlcNAc transferase (OGT) inhibitor, it can reduce proliferation and viability of prostate cancer cells in vitro.

Price and Availability

Size Price Shipping out time Quantity
10mg USD 385 2 Weeks
50mg USD 1250 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-01-26. Prices are subject to change without notice.

ST 045849, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 471036
Name: ST 045849
CAS#: 442665-87-4
Chemical Formula: C23H27ClN2O3S
Exact Mass: 446.1431
Molecular Weight: 446.99
Elemental Analysis: C, 61.80; H, 6.09; Cl, 7.93; N, 6.27; O, 10.74; S, 7.17

Synonym: ST 045849, ST045849, ST-045849

IUPAC/Chemical Name: (Z)-3-(2-(adamantan-1-yl)ethyl)-2-((4-chlorophenyl)imino)-4-oxo-1,3-thiazinane-6-carboxylic acid


InChi Code: InChI=1S/C23H27ClN2O3S/c24-17-1-3-18(4-2-17)25-22-26(20(27)10-19(30-22)21(28)29)6-5-23-11-14-7-15(12-23)9-16(8-14)13-23/h1-4,14-16,19H,5-13H2,(H,28,29)/b25-22-

SMILES Code: O=C(C(S/C(N1CCC2(C3)CC4CC3CC(C4)C2)=N\C5=CC=C(Cl)C=C5)CC1=O)O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1. Kim al; Impact of protein O-GlcNAcylation on neural tube malformation in diabetic embryopathy; Sci Rep. 2017 Sep 11;7(1):11107. doi: 10.1038/s41598-017-11655-6.

2. Itkonen HM et al.; Inhibition of O-GlcNAc transferase activity reprograms prostate cancer cell metabolism; Oncotarget. 2016 Mar 15;7(11):12464-76. doi: 10.18632/oncotarget.7039.

3. Kim EJ et al.; Versatile O-GlcNAc transferase assay for high-throughput identification of enzyme variants, substrates, and inhibitors; Bioconjug Chem. 2014 Jun 18;25(6):1025-30. doi: 10.1021/bc5001774. Epub 2014 Jun 2

4. Victor V. Lima et al.; O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway; Cardiovasc Res. 2011 Feb 15; 89(3): 614–622.